期刊文献+

基于分子对接方法进行金银花、连翘抗流感病毒H7N9的研究 被引量:8

Molecular Docking- based Study on the Anti- influenza H7N9 of Flos Lonicerae and Fructus Forsythiae
下载PDF
导出
摘要 目的从金银花-连翘药对中寻找能够应对流感病毒H7N9的潜在抑制剂。方法以H7N9神经氨酸酶N9及其两种突变型N9-R294K和N9-R292K为受体,以金银花-连翘中24个化合物为配体,应用分子对接方法研究配体与受体之间的相互作用关系。结果研究发现金银花-连翘药对中19个成分与H7N9神经氨酸酶发生作用。其中M1、M4、M5、M7、M8、M10、M12、M14、M16、M17、M19、M22、M23等小分子是金银花-连翘药对作用H7N9神经氨酸酶的主要化合物。分子对接结果显示M4和M22与N9、N9-R294K、N9-R292K的对接分值分别为9.86、11.42、8.02、8.69、11.15、7.24;M5、M10与N9-R294K对接得分为10.36、8.36,均显著高于对照组奥司他韦羧酸盐。结论金银花-连翘药对能够通过分子间的协同效应有效防治H7N9流感病毒。M4(连翘酯苷A)和M22(亚油酸乙酯)可以作为流感病毒H7N9(包括两种突变型)的潜在抑制剂进行进一步研究开发。 Objective: The purpose of this paper is to find the potential inhibitors of influenza H7N9 from herbal medicine Flos Lonicerae and Fructus Forsythiae. Methods: In this study,we used the general H7N9 neuraminidase( N9)and oseltamivir- resistant neuraminidase including N9- R294 K and N9- R292 K mutations as acceptors and employed the 24 small molecules in Flos Lonicerae and Fructus Forsythiae as ligands to perform the molecular docking for exploring the binding abilities between these small molecules and neuraminidase. Results: According to the docking scores( =6),we found the 19 components in the herbs showed obvious synergistic effect to fight influenza H7N9. Comparing the docking results with oseltamivir. M1,M4,M5,M7,M8,M10,M12,M14,M16,M17,M19,M22,M23 showed high scores which could be as the main composition of Flos Lonicerae and Fructus Forsythiae to inhibit H7N9. Among these molecules,M4,M5,M10,M22 present oseltamivir- comparable high scores with neuraminidase,but M4 and M22showed interaction with 3 different subtypes of N9. Conclusion: Flos Lonicerae and Fructus Forsythiae can inhibit H7N9 neuraminidase including drug- resistant mutants through synergistic effect and the small molecules M4( Forsythoside A)and M22( Ethyl linoleate) can be as potential inhibitors for neuraminidase of H7N9.
机构地区 陕西中医药大学
出处 《现代中医药》 CAS 2016年第2期75-78,共4页 Modern Chinese Medicine
基金 陕西省科技厅项目(2014JQ4148) 浙江省高校生物学重中之重学科2015年开放基金(2015D12)
关键词 H7N9 突变 分子对接 金银花、连翘 抑制剂 H7N9 mutations molecular docking Flos Lonicerae and Fructus Forsythiae inhibitors
  • 相关文献

参考文献13

  • 1Gao R. et al. Human infection with a novel avian - origin influenza A (HTN9) virus. New England Journal of Medi- cine, 2013, 368(20) :1888 - 1897.
  • 2Uyeki TM, Cox NJ. Global concerns regarding novel influ- enza A (H7N9) virus infections. New England Journal of Medicine, 2013, 368(20) :1862 - 1864.
  • 3Hansen E, Day T, Arino J. et al. Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks. Ca- nadian journal of infectious diseases and medical microbiol- ogy, 2010, 21(1) :28 -63.
  • 4Hu Y. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding amt emergence of antiviral re- sistaJme. Lancet. 2013,381 (9885) :2273 - 2279.
  • 5Samson M, Pizzomo A, Abed Y. el al. lniiuenza ~'irus re- sistance to neuraminidase inhibitocs. ,kntiviral tteseareh, 2013, 98(2) :174 - 185.
  • 6Whitley R J, Boueher CA, Lina B. el al. Global as:-~essment of resistance to neuraminidase inhibit(,rs: 2008 -2011. The intluenza resistance information stady (IRIS). Clini- cal infectious diseases, 2013, 56(9 ) , 1197 - 1205.
  • 7Zekun Liu, Junpeng Zhao, Weieheo l,i. e~ al. Molectdar Docking of Potential Inhibitors tbr lnflue~ml I!7N9. Com- putational and Mathematical Methods in Medici~te, 2015,480764.
  • 8Woods CJ, Malaisree M, I.ong B. et al. (~ompu',ational Assay of H7N9 Influenza Neuramlnida+e t+leveats it292 K Mutation Reduces Drug Binding ~kffinity. Scientific r~- ports, 2013,3:3561.
  • 9邢学锋,陈飞龙,罗佳波.金银花、连翘药对配伍挥发油成分的GC-MS分析[J].中药新药与临床药理,2009,20(4):358-360. 被引量:18
  • 10潘家祜.基于网络药理学的药物研发新模式[J].中国新药与临床杂志,2009,28(10):721-726. 被引量:68

二级参考文献40

  • 1张伯礼,王永炎.方剂关键科学问题的基础研究——以组分配伍研制现代中药[J].中国天然药物,2005,3(5):258-261. 被引量:159
  • 2KOLA I, LANDIS J. Can the pharmaceutical industry reduce attrition rates?[J]. Nat Rev Drug Discov, 2004, 3 (8) : 711-716.
  • 3BARTER PJ, CAULFIELD M, ERIKSSON M, et al. Effects of torcetrapib in patients at high risk for coronary events[J]. N Engl J Med, 2007, 357(21): 2109-2122.
  • 4WAGNER BK, KITAMI T, GILBERT TJ, et al. Large-scale chemical dissection of mitochondrial function[J]. Nat Biotechnol, 2008, 26(3) : 343-351.
  • 5HOPKINS AL. Network pharmacology: the next paradigm in drug discovery[J]. Nat Chem biol, 2008, 4(11 ) : 682-690.
  • 6PAOLINI GV, SHAPLAND RH, van HOORN WP, et al. Global mapping of pharmacological space[J]. Nat Biotechnol, 2006, 24 (7): 805-815.
  • 7HOPKINS AL. Network pharmacology[J]. Nat Biotechnol, 2007, 25(10): 1110-1111.
  • 8GOH KI, CUSICK ME, VALLE D, et al. The human disease network[J]. PNAS, 2007, 104(21) : 8685-8690.
  • 9YILDIRIM MA, GOH KI, CUSICK ME, et al. Drug-target network[J]. Nat Biotechnol, 2007, 25(10): 1119-1126.
  • 10KINGSMORE SF, LINDQUIST IE, MUDGE J, et al. Genomewide association studies: progress and potential for drug discovery and development[J]. Nat Rev Drug Discov, 2008, 7 (3): 221-230.

共引文献91

同被引文献132

引证文献8

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部